Craig Hallum Initiates Coverage on Personalis (NASDAQ:PSNL)

Craig Hallum assumed coverage on shares of Personalis (NASDAQ:PSNL) in a research note released on Monday, MarketBeat reports. The brokerage issued a buy rating and a $8.00 target price on the stock.

Several other equities research analysts also recently weighed in on PSNL. HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of Personalis in a report on Friday, February 28th. Lake Street Capital increased their price objective on Personalis from $7.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. Finally, Needham & Company LLC decreased their price target on Personalis from $7.25 to $7.00 and set a “buy” rating for the company in a report on Friday, February 28th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $7.80.

Personalis Trading Up 2.2 %

PSNL stock opened at $3.67 on Monday. The company has a market capitalization of $323.93 million, a P/E ratio of -2.18 and a beta of 1.73. Personalis has a twelve month low of $1.14 and a twelve month high of $7.20. The business has a 50 day simple moving average of $4.83 and a 200-day simple moving average of $4.88.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.09. The business had revenue of $16.80 million during the quarter, compared to the consensus estimate of $15.48 million. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. Research analysts predict that Personalis will post -1.4 EPS for the current fiscal year.

Institutional Investors Weigh In On Personalis

Several hedge funds have recently modified their holdings of PSNL. Lightspeed Management Company L.L.C. acquired a new stake in shares of Personalis during the fourth quarter worth $47,169,000. abrdn plc purchased a new position in Personalis in the fourth quarter worth $1,722,000. Dimensional Fund Advisors LP raised its position in Personalis by 144.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 410,083 shares of the company’s stock worth $2,372,000 after acquiring an additional 242,141 shares in the last quarter. Jane Street Group LLC raised its position in Personalis by 144.3% in the fourth quarter. Jane Street Group LLC now owns 401,314 shares of the company’s stock worth $2,320,000 after acquiring an additional 237,033 shares in the last quarter. Finally, Walleye Capital LLC purchased a new position in Personalis in the third quarter worth $897,000. 61.91% of the stock is owned by institutional investors and hedge funds.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.